Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the performance characteristics of a novel [18F] amyloid detection
ligand (18F]-AV-45) with respect to its ability to distinguish patients with
clinically-diagnosed probable Alzheimer's disease from cognitively normal elderly subjects
and to independently compare its diagnostic performance characteristics with the ability of
[11C]PIB to correctly categorize the same subjects.
SPECIFIC HYPOTHESES
1. Individuals with a clinical diagnosis of probable Alzheimer's disease will have
increased brain retention of [18F]-AV-45 compared to cognitively normal elderly
individuals.
2. There will be no clinically meaningful difference in the amyloid retention performance
characteristics of [18F]-AV-45 and [l1C]PIB.
Phase:
Phase 2
Details
Lead Sponsor:
Avid Radiopharmaceuticals
Collaborators:
American College of Radiology Imaging Network General Electric